Palvella Therapeutics
PVLA
96 hedge funds and large institutions have $107M invested in Palvella Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 10 closing their positions.
25% more capital invested
Capital invested by funds: $85.9M → $107M (+$21.2M)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
1% more funds holding
Funds holding: 95 → 96 (+1)
0.01% less ownership
Funds ownership: 0.84% → 0.82% (-0.01%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.51M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.86M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.48M |
| 4 |
BlackRock
New York
|
+$621K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$599K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8.06M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$4.42M |
| 3 |
Morgan Stanley
New York
|
-$980K |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$602K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$414K |
PVLA Hedge Fund Activity: Q2 2020 in Review
96 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2020, worth a combined $107M — up 25% from $85.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PVLA positions and 10 closed out — a net gain of 2 holders — while 31 added to existing stakes and 26 trimmed.
The largest buyer was Candriam SCA, adding an estimated $2.51M. The largest seller was BVF Inc, cutting an estimated $8.06M.
- 96 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2020, up from 95 in Q1 2020.
- Funds reported $107M of Palvella Therapeutics stock for Q2 2020, up 25% quarter-over-quarter.
- 12 funds opened new Palvella Therapeutics positions in Q2 2020 and 10 closed out, a net change of +2 holders.
- The largest Palvella Therapeutics buyer in Q2 2020 was Candriam SCA, an estimated $2.51M added.
- The largest Palvella Therapeutics seller in Q2 2020 was BVF Inc, an estimated $8.06M sold.
Based on aggregated 13F filings for Q2 2020.